4105-38-8 | 2',3',5'-Triacetyluridine

Packsize	Purity	Availability	Price	Discounted Price
5g	97%	in stock	$7.00	$5.00
25g	97%	in stock	$28.00	$19.00
100g	97%	in stock	$92.00	$65.00

Description

• Catalog Number: AB59768
• Chemical Name: 2',3',5'-Triacetyluridine
• CAS Number: 4105-38-8
• Molecular Formula: C15H18N2O9
• Molecular Weight: 370.3114
• MDL Number: MFCD00023795
• SMILES: CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@H](O[C@H]1n1ccc(=O)[nH]c1=O)COC(=O)C

Computed Properties

• Complexity: 660
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 8
• XLogP3: -0.5

Literature

• A rational approach to the regioselective deacetylation of 2',3',5'-tri-O-acetyluridine by Novozym 435 catalysed alcoholysis.

  Biochimica et biophysica acta 20120401

• Use of uridine triacetate for the management of fluorouracil overdose.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111001

• Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement.

  PloS one 20110101

• Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients.

  Experimental and clinical psychopharmacology 20080601

• Phthalocyanine-based molecularly imprinted polymers as nucleoside receptors.

  Metal-based drugs 20080101

• Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.

  Neurobiology of disease 20061201

• Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.

  Investigational new drugs 20061101

• 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.

  Cancer chemotherapy and pharmacology 20060701

• Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.

  Diseases of the colon and rectum 20060301

• Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine.

  Brain research 20051220

• Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.

  Neuromolecular medicine 20040101

• Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease.

  Brain research 20031219

• Synthesis and hypnotic activities of 4-thio analogues of N3-substituted uridines.

  Chemical & pharmaceutical bulletin 20010901